Mainstream

Atai life sciences and beckley psytech announce positive topline results from the phase 2b study of bpl 003 in patients with treatment resistant depression

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single dose

You might also be interested in reading Solana ETF inflows top $1 Billion; SOL holders earn up to $7,000 daily.

July 1, 2025
In Mainstream